« IAG Research's List of Most Memorable TV Commercial 2006-2007 | Main | Energy Drinks Mask Alcohol Intoxication »

Nov 4
Double Damages in Drug Pricing Case

AstraZeneca's (NYSE:AZN)  and Bristol-Myers Squibb (NYSE:BMY) have been ordered to pay double damages in a case over false mark-ups of U. S drug prices through 2003.

U.S District Judge Patti Saris, of Massachusetts District Court, found that the two companies had acted willfully and ordered AstraZeneca to pay more than $12.9 million in damages and Bristol-Myers must pay almost $700,000.

The class action suit stated that drug makers boosted published average wholesale prices which were the basis for reimbursements from Medicare, state governments and private insurers until 2003.

Saris found that the two companies grossly inflated the prices of drugs in a ruling in June. She said that the companies "knew that Medicare beneficiaries, and thus their insurers, were locked by statute into paying twenty-percent of grossly inflated phony AWPs, which bore no relation to any average of wholesale prices in the marketplace."

AstraZeneca released a statement after the ruling stating: "AstraZeneca is disappointed with today's ruling and we intend to appeal. We believe the ruling is unsupported as the conduct at issue was the result of highly competitive conditions in the pharmaceutical marketplace, which led to discounting. The Court's prior ruling on liability is thus profoundly anti- competitive.
AstraZeneca has competed responsibly with respect to pricing and marketing of drugs and we firmly believe that we have acted at all times in accordance with the law.
The plaintiffs are fully aware of AWP pricing and still use AWP as a reimbursement benchmark today. The result of AstraZeneca's conduct in this case was to keep a lower cost product competitive under the Government's reimbursement system, thereby saving Medicare and patients millions of dollars."

Spokesman Tony Plohoros said "Bristol-Myers Squibb has long maintained that it is not responsible for the average wholesale price reimbursement benchmark used by private insurers and medicare, and that its own pricing sales and marketing practices were fair and reasonable."

Both companies intend to appeal the ruling.

[Source: PRNewsWire and Yahoo News]

related entries


0 Comments/Trackbacks




submit a trackback

TrackBack URL for this entry:

post a comment

Name, Email Address, and URL are not required fields.





Comment Preview

« IAG Research's List of Most Memorable TV Commercial 2006-2007 | Main | Energy Drinks Mask Alcohol Intoxication »

Advertise

Watch the Digital Health Revolution


sponsored ads



subscribe


Prefer Email?
Subscribe below-

Enter your Email:


Powered by FeedBlitz What's this?

Current News

Support This Blog

top blogs

business social media

Use these fast growing business social media sites to promote your business, feature your products, spotlight your business leaders, create links, and drive traffic back to your company site, all for free!

BIZZlogos - Add your logo - free link to your site
BIZZphotos - Add photos of your products and people
BIZZprofiles - Submit your profile and build your online visibility
BIZZspotlight - Spotlight your business with free links
BIZZvideos - Videos about businesses, products and business people.
BIZZbites - "Digg" for Business - Submit your articles and posts

know more media network

View Network Map

Network Feed List (OPML)

Know More Media Network
Feed


we support unitus

PRWeb

Influencer



PharmaGazette is a member of the Know More Media network of business related blogs.

Here are some current headlines from some of our business publications:

ProductivityGoal

CallCenterScript

AdHurl

TheBizofKnowledge

LandingTheDeal

CustomersAreAlways

HealthCareVox

BrainBasedBusiness

TheInsurancePolicy

MarketingBlurb